Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications

López-Cerero, Lorena; Navarro, M.D.; Bellido, Mar; Martín-Peña, Almudena; Viñas, Laura; Cisneros, José Miguel; Gómez-Langley, Sara Louise; Sánchez-Monteseirín, Herminia; Morales, Isabel; Pascual, Álvaro; Rodríguez-Baño, Jesús

doi:10.1093/jac/dkt405

Cited by 55 publications

(59 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies reported similar prevalences of E. coli ST131 among the non-ESBLproducing isolates: 10% in France (2008 to 2009), 12% in Spain (2010), and 13% in each of the other two studies, carried out in the United States (2007 to 2012). However, the reported prevalence among ESBL-producing isolates was higher in the United States (49 to 50%) than in France (36%) or Spain (23%) (16,54,156,161). ESBL-producing isolates and 72% among the ESBL producers (42).…”

Section: Prevalence and Epidemiology Of E Coli St131 Among Human CLImentioning

confidence: 96%

“…A very small number of studies (16,54) have provided information about resistance to various antibiotic families in E. coli ST131 isolates, comparing the results obtained with those for non-ST131 E. coli isolates producing or not producing ESBL (Tables 2 and 3). For ESBL-producing isolates, these studies showed that E. coli ST131 isolates were consistently more frequently resistant to amikacin than non-ST131 isolates and potentially more frequently resistant to amoxicillin-clavulanic acid, piperacillin-tazobactam, or ciprofloxacin; they were also more frequently suscep- tible to gentamicin or co-trimoxazole than non-ST131 isolates, depending on the country considered (Table 2).…”

Section: Antibiotic Resistancementioning

confidence: 99%

“…Four studies to date have investigated the factors associated with clinical isolates of E. coli ST131 (54,156,162,208). These studies were performed in different countries (Taiwan, one hospital be- .…”

Section: Factors Associated With Clinical Isolates Of E Coli St131mentioning

confidence: 99%

“…These studies differed in terms of the methodologies used. The study designs were different, with a case-control design used in France (case, a patient with a CTX-M-producing ST131 E. coli isolate from any clinical sample; control, a patient with an ESBLproducing non-ST131 E. coli clinical isolate from any sample) and in Spain (case 1, a patient with a non-ESBL-producing ST131 E. coli clinical isolate; control 1, a patient with a non-ESBL-producing non-ST131 E. coli clinical isolate; case 2, a patient with an ESBL-producing ST131 E. coli isolate from any clinical sample; and control 2, a patient with an ESBL-producing non-ST131 E. coli clinical isolate from any sample) (54,208). In contrast, cohort studies were carried out in Taiwan (cases, patients with an ESBLproducing ST131 E. coli isolate causing bacteremia; controls, patients with an ESBL-producing non-ST131 E. coli isolate causing bacteremia) and the United States (cases, patients with an E. coli ST131 isolate from any sample; controls, patients with a non-ST131 E. coli isolate from any sample) (156,162).…”

Section: Factors Associated With Clinical Isolates Of E Coli St131mentioning

confidence: 99%

“…The MLST method was applied to all E. coli isolates included in the Taiwanese and French studies (162,208). Screening methods were carried out in both the Spanish study (PCR for 025b rfb and allele 3 of the pabB gene in B2 group isolates) and in the American study (detection of single-nucleotide polymorphisms of the mdh and gyrB genes associated with the two-locus clonal typing strategy based on the sequencing of the fumC and fimH genes in B2 group E. coli isolates) (54,156). A third difference concerned the populations included: adult patients in the Taiwanese, French, and Spanish studies and both adults and children in the American study.…”

Section: Factors Associated With Clinical Isolates Of E Coli St131mentioning

confidence: 99%

See 4 more Smart Citations

Escherichia coli ST131, an Intriguing Clonal Group

2014

View full text Add to dashboard Cite

SUMMARY In 2008, a previously unknown Escherichia coli clonal group, sequence type 131 (ST131), was identified on three continents. Today, ST131 is the predominant E. coli lineage among extraintestinal pathogenic E. coli (ExPEC) isolates worldwide. Retrospective studies have suggested that it may originally have risen to prominence as early as 2003. Unlike other classical group B2 ExPEC isolates, ST131 isolates are commonly reported to produce extended-spectrum β-lactamases, such as CTX-M-15, and almost all are resistant to fluoroquinolones. Moreover, ST131 E. coli isolates are considered to be truly pathogenic, due to the spectrum of infections they cause in both community and hospital settings and the large number of virulence-associated genes they contain. ST131 isolates therefore seem to contradict the widely held view that high levels of antimicrobial resistance are necessarily associated with a fitness cost leading to a decrease in pathogenesis. Six years after the first description of E. coli ST131, this review outlines the principal traits of ST131 clonal group isolates, based on the growing body of published data, and highlights what is currently known and what we need to find out to provide public health authorities with better information to help combat ST131.

show abstract

Section: Prevalence and Epidemiology Of E Coli St131 Among Human CLImentioning

confidence: 96%

Section: Antibiotic Resistancementioning

confidence: 99%

Section: Factors Associated With Clinical Isolates Of E Coli St131mentioning

confidence: 99%

Section: Factors Associated With Clinical Isolates Of E Coli St131mentioning

confidence: 99%

Section: Factors Associated With Clinical Isolates Of E Coli St131mentioning

confidence: 99%

See 3 more Smart Citations

Escherichia coli ST131, an Intriguing Clonal Group

2014

View full text Add to dashboard Cite

show abstract

Proteomics of septicemic Escherichia coli

Otto

Biran

Sura

et al. 2016

Proteomics Clinical Apps

View full text Add to dashboard Cite

Virulent strains of Escherichia coli have become a major cause of infections, especially in hospitals and institutions, and result in high morbidity and mortality, due to the widespread antibiotic resistance. The infections usually start as complications of urinary tract infections or invasive medical procedures. Septicemic bacteria have to go through the blood stream, where they are exposed to a variety of stress conditions. The most difficult of these is the presence of the immune complement, which is strongly bactericidal. However, recently it has become clear that the nutritional immunity (metabolic stress) of serum is just as important. Thus, as shown by proteomic analyses, septicemic E. coli can cope with this latter stress condition by globally modifying the expression of a variety of metabolic genes. These include genes involved in amino acid metabolism and in metal homeostasis, whose robust regulation of expression appears to be critical for surviving the metabolic immunity of serum. Recognition of the nutritional immunity and the molecular mechanisms that enable septicemic bacteria to overcome it are the focus of this paper.

show abstract

The Role of AcrAB–TolC Efflux Pumps on Quinolone Resistance of E. coli ST131

et al. 2018

View full text Add to dashboard Cite

E.coli ST131 is a global concern because of its high multi-drug resistance and several virulence factors. In this study, the contribution of acrAB-TolC efflux system of E.coli ST131 to fluoroquinolone resistance was evaluated. A total of non-repetitive 111 ciprofloxacin resistant E.coli isolates were included in the study. Multi-locus sequence typing (MLST) was used for genotyping. Expressions of acrA, acrB and tolC efflux pump genes were measured by RT-PCR. Mutations in marA, gyrA, parC, and aac(6')-lb-cr positivity were studied by Sanger sequencing. Sixty-four (57.7%) of the isolates were classified as ST131 and 52(81.3%) of the ST131 isolates belonged to H30-Rx subclone. In ST131, CTX-M 15 positivity (73%) and aac(6')-lb-cr carriage (75%) were significantly higher than non-ST131 (12.8% and 51%, respectively) (p<0.05). The ampicillin-sulbactam (83%) resistance was higher, gentamicin resistance (20%) was lower in ST131 than non-ST131 (64% and 55%, respectively) (p=0.001 and p=0.0002). Number of the isolates with MDR or XDR profiles did not differ in both groups. Multiple in-dels (up to 16) were recorded in all quinolone resistant isolates. However, marA gene was more overexpressed in ST131 compared to non-ST131 (median 5.98 vs 3.99; P=0.0007). Belonging to H30-Rx subclone, isolation site, ciprofloxacin MIC values did not correlate with efflux pump expression. In conclusion, the marA regulatory gene of AcrAB-TolC efflux pump system has a significant impact on quinolone resistance and progression to MDR profile in ST131 clone. Efflux pump inhibitors might be alternative drugs for the treatment of infections caused by E.coli ST131 if used synergistically in combination with antibiotics.

show abstract

Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications

Abstract: Previous use of antibiotics selecting for ST131 isolates was the main modifiable risk factor for infections caused by these isolates. Our results also suggest that the clinical virulence of ST131 is not higher than that of other common E. coli causing infections.

Cited by 55 publications

References 29 publications

Escherichia coli ST131, an Intriguing Clonal Group

Escherichia coli ST131, an Intriguing Clonal Group

Proteomics of septicemic Escherichia coli

The Role of AcrAB–TolC Efflux Pumps on Quinolone Resistance of E. coli ST131

Contact Info

Product

Resources

About